
Abstract Introduction Patients with mechanical heart valves in pregnancy are at a substantially higher risk of adverse maternal and fetal outcomes. Management of patients with mechanical heart valves poses a unique challenge, and strategies for anticoagulation in these patients remain controversial. The goal of this project was to determine rates of adverse maternal and perinatal outcomes in patients with mechanical valves compared to those with bioprosthetic valves, and assess outcomes in patients with mechanical valves using low molecular weight heparin and warfarin. Methods A retrospective query was performed using Epic Cosmos to evaluate pregnancies affected by mechanical and bioprosthetic heart valves between January 1, 2023 and January 1, 2026. Patient demographics and rates of adverse cardiac outcomes in the perinatal period, including heart failure, arrhythmia, and stroke, were assessed. The rate of anticoagulation with low molecular weight heparin and warfarin in patients with mechanical heart valves was evaluated, and cardiac and perinatal outcomes were determined and compared between groups. Rare outcomes were reported as <10 to protect patient privacy. Results Baseline demographics between patients with mechanical and bioprosthetic heart valves were similar. Rates of heart failure (22.9%) and stroke (11.7%) were significantly higher in patients with mechanical compared to bioprosthetic heart valves, though the rates of maternal arrhythmia were similar between groups. Valve thrombosis was a rare outcome for patients with mechanical valves, with fewer than 10 events in the study sample. Perinatal outcomes including preterm and cesarean delivery were similar between groups. Conclusion In conclusion, mechanical heart valves are associated with high rates of heart failure and stroke in pregnancy. Rates of adverse events may be similar for patients using low molecular weight heparin compared to warfarin for anticoagulation in pregnancy.
Abstract Background Dapagliflozin (DAPA), a sodium‐glucose co‐transporter inhibitor (SGLT2i), has been shown to prevent the development of heart failure and slow the progression of pre‐existing heart failure; however, there are limited data published to demonstrate the safety of postpartum lactating individuals taking SGLT2is. Methods Lactating patients received two oral doses of 10 mg DAPA over a 48‐h period. Breast milk and plasma were collected 2 h after the second dose. Samples were processed via liquid chromatography mass spectrometry (LCMS) analysis. Breast milk concentrations of DAPA were divided by plasma concentrations of DAPA (in ng/mL). The absolute (AID; i.e., daily infant dose) and relative infant doses (RID) were performed. An RID of 10% was considered the limit of acceptable exposure. Results Three of four participants were able to produce enough sample for assessment. Across three samples, the mean DAPA concentrations in plasma and breast milk were 77.6 ± 10.2 and 16.8 ± 3.1 ng/mL, respectively. Mean AID was 8.04 × 10−3 ± 2.50 × 10−3 mg/day and the mean RID was 7.73 ± 3.9%. Conclusions This study demonstrates that human breast milk collected at peak anticipated maternal concentrations of DAPA has a mean RID below 10%. This is the first report of human transfer levels for DAPA, generating preliminary lactation‐specific pharmacokinetic data that are essential to support evidence‐based treatment of breastfeeding individuals and reduce disparities in their representation within cardiovascular therapeutic research.
Abstract Background Traditional US prenatal care typically includes 12–14 standardized in‐person visits. COVID‐19‐related barriers accelerated adoption of blended virtual/in‐person prenatal care, but evidence from large, diverse populations is limited. Objective To compare perinatal outcomes after implementation of a blended prenatal care model versus traditional in‐person care in a large health maintenance organization. Methods Retrospective cohort study in Kaiser Permanente Northwest and Southern California comparing blended care (cases, July 22, 2022 to December 31, 2024) with traditional in‐person care (controls, January 1, 2018 to December 31, 2019). Groups were compared using t‐tests/Wilcoxon and chi‐square tests; multivariable logistic regression estimated adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Results Among 47,577 patients (473 cases; 47,104 controls), cases were older at delivery (mean = 32.0 [SD = 4.6] vs. 30.4 [4.9] years, p < 0.0001), more likely to be non‐Hispanic White (68.9% vs. 26.5%, p < 0.0001), had higher median household income, and higher rates of publicly funded coverage (15.9% vs. 9.1%, p < 0.0001). Cases had fewer nulliparous women (20.9% vs. 47.5%, p < 0.0001), higher smoking rates (9.5% vs. 2.7%), and less likely to initiate prenatal care in the first trimester (92.6% vs. 96.8%). Cases had fewer in‐person visits (mean = 6.2 [2.7] vs. 15.7 [6.2], p < 0.0001), more virtual visits (3.2 [1.4] vs. 1.0 [1.4], p < 0.0001), and fewer total visits (9.4 [3.2] vs. 16.7 [6.5], p < 0.0001). Depression screening was more frequent in cases (84.1% vs. 45.9%, p < 0.0001). Compared to controls, cases had lower odds of preterm premature rupture of membranes (PPROM) (aOR, 0.17; 95% CI, 0.05–0.58), preterm birth <37 weeks (aOR, 0.37; 95% CI, 0.22–0.61), and stillbirth (aOR, 0.14; 95% CI, 0.03–0.70), but higher odds of non‐reassuring fetal heart rate tracing (aOR, 1.30; 95% CI, 1.06–1.60), gestational diabetes (aOR, 3.75; 95% CI, 2.80–5.01), and intrauterine growth restriction (IUGR; aOR, 2.46; 95% CI, 1.42–4.25). No significant differences were observed in placenta previa, chorioamnionitis, cesarean birth, postpartum hemorrhage, macrosomia, placental abruption, preeclampsia/eclampsia, or maternal length of stay more than 2 days. Conclusions Blended virtual/in‐person prenatal care was associated with comparable perinatal outcomes despite fewer visits. Lower odds of preterm birth, PPROM, and stillbirth and higher odds of non‐reassuring fetal heart rate tracings, gestational diabetes, and IUGR suggest that blended care is feasible for low‐risk pregnancies, with attention to strengthening monitoring.
Abstract Background Preterm birth is associated with an increased rate of serious maternal complication compared with those who deliver at term. However, data are limited on risk factors for maternal morbidity and mortality specifically in the setting of preterm birth. Improved understanding of risk factors for morbidity in patients with preterm birth can help optimize interventions to best support patients experiencing preterm birth. Objective To assess associations between obstetric factors and maternal morbidities and mortality among patients who gave birth less than 35 weeks’ gestation. Study design This is a secondary analysis of a multicenter registry of gravidas carrying singletons or twins who gave birth at 16 0/7 to 34 6/7 weeks’ gestation January through August 2019. The primary outcome was a maternal morbidity and mortality composite (blood transfusion, postpartum hemorrhage, maternal sepsis, stroke, thromboembolism, intensive care unit admission, or death) during the delivery hospitalization. Factors were compared between those with and without the composite outcome to identify statistically significant variables. Those factors were then used to create a parsimonious multivariable logistic regression model with adjusted odds ratio (aOR) and 95% confidence intervals (CIs) using a backward strategy. We estimated area under the curve to quantify the predictive ability of these factors for the primary outcome. Results The analysis was based on 6660 patients, of whom 15.1% experienced the primary composite outcome. Factors associated with increased odds of the outcome included increasing maternal age, use of assisted reproductive technology, twin gestation, preeclampsia, placental abruption and cesarean delivery—aOR ranged from 1.02 [1.01–1.04] for maternal age (continuous) to 2.55 [2.08–3.14] for abruption. In contrast, nulliparity, gestational diabetes, preterm prelabor rupture of membranes (PPROM), and later birth gestational age were associated with decreased odds of the primary outcome—aOR ranging from 0.96 [0.95–0.98] for gestational age (continuous) to 0.54 [0.44–0.66] for PPROM. The model with these factors had low to moderate predictive ability (AUC 0.68 [0.66–0.69]). Conclusion Among individuals who experienced preterm birth before 35 weeks, multiple factors were associated with maternal morbidity and mortality. The factors together modestly discriminate maternal morbidity or mortality.
Abstract Introduction Activity restriction and bedrest are frequently prescribed in pregnancy with the goal of preventing preterm birth, despite evidence that these practices are ineffective and harmful. While these practices persist, the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal‐Fetal Medicine (SMFM) guidelines recommend against the routine use of activity restriction. Understanding clinicians’ perspectives related to guideline‐informed activity recommendations is essential to inform deimplementation strategies. This study aims to identify barriers and facilitators of deimplementation of activity restriction in pregnancy from the perspective of prenatal care clinicians, using the Consolidated Framework for Implementation Research 2.0 (CFIR) in a qualitative approach. Methods We conducted a qualitative study using semi‐structured individual interviews with prenatal care clinicians ( n = 14) at sites within or affiliated with a large urban academic medical center between November 2024 and September 2025. Participants included obstetrician‐gynecologists, a maternal‐fetal medicine physician, a family medicine physician, nurses, a certified nurse midwife, and office staff from both academic and community practice settings. Interviews were coded and analyzed using NVivo software. Emergent themes were mapped to CFIR domains and constructs. Results Clinicians universally endorsed the benefits of physical activity in pregnancy but demonstrated significant knowledge gaps regarding current evidence and professional society guidelines. No clinicians recognized the inverse relationship between physical activity and preterm birth. Many followed outdated guidance, citing contraindications to exercise that have been removed from current ACOG recommendations. Key barriers to deimplementation included a perceived lack of evidence, patient anxiety, social media misinformation, cultural expectations around rest during pregnancy, and fear of rare adverse outcomes. Trust in ACOG and SMFM as credible sources and system‐level infrastructure such as consensus meetings and standardized recommendations were described as facilitating decision support. Conclusion(s) In this exploratory, single‐institution study, deimplementation of activity restriction in pregnancy was less constrained by clinician opposition to physical activity and more by knowledge gaps, patient expectations, and fear of rare adverse outcomes. Strategies that leverage existing clinician trust in professional society guidelines and address condition‐specific uncertainty may facilitate practice change.